| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.855 | 0.004 | 0.855 | Anticonvulsant | 0.748 0.005 DBMET00285 0.641 0.005 DBMET02951 | ||
| 0.752 | 0.003 | 0.752 | Anesthetic general | 0.686 0.004 DBMET00285 0.373 0.02 DBMET02951 | ||
| 0.572 | 0.003 | 0.579 | Nav1.1 sodium channel blocker | 0.579 0.003 DBMET00285 0.09 0.081 DBMET02951 | DBMET00285 | |
| 0.549 | 0.003 | 0.563 | Lipocortins synthesis antagonist | 0.563 0.003 DBMET00285 0.15 0.105 DBMET02951 | DBMET00285 | |
| 0.52 | 0.044 | 0.52 | Analgesic | 0.222 0.212 DBMET02951 | ||
| 0.47 | 0.028 | 0.523 | Spasmolytic | 0.523 0.02 DBMET00285 0.274 0.081 DBMET02951 | DBMET00285 | |
| 0.452 | 0.041 | 0.512 | GABA C receptor rho-3 antagonist | 0.452 0.041 DBMET00285 0.512 0.023 DBMET02951 | DBMET02951 | |
| 0.377 | 0.008 | 0.401 | Nav1.2 sodium channel blocker | 0.401 0.007 DBMET00285 0.195 0.036 DBMET02951 | DBMET00285 | |
| 0.372 | 0.027 | 0.548 | Psychostimulant | 0.548 0.008 DBMET00285 0.216 0.072 DBMET02951 | DBMET00285 | |
| 0.415 | 0.088 | 0.492 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.456 0.058 DBMET00285 0.492 0.037 DBMET02951 | DBMET02951 | |
| 0.291 | 0.006 | 0.291 | 5 Hydroxytryptamine 7 antagonist | 0.22 0.01 DBMET00285 | ||
| 0.312 | 0.03 | 0.312 | Growth hormone agonist | 0.247 0.044 DBMET00285 0.297 0.033 DBMET02951 | ||
| 0.281 | 0.007 | 0.329 | Nav1.6 sodium channel blocker | 0.329 0.005 DBMET00285 0.149 0.055 DBMET02951 | DBMET00285 | |
| 0.263 | 0.012 | 0.521 | Ferrochelatase inhibitor | 0.263 0.012 DBMET00285 0.521 0.002 DBMET02951 | DBMET02951 | |
| 0.318 | 0.074 | 0.318 | Calcium channel activator | 0.219 0.186 DBMET00285 0.281 0.112 DBMET02951 | ||
| 0.253 | 0.014 | 0.31 | Nav1.3 sodium channel blocker | 0.31 0.008 DBMET00285 0.122 0.072 DBMET02951 | DBMET00285 | |
| 0.232 | 0.008 | 0.232 | Opioid kappa receptor antagonist | |||
| 0.227 | 0.017 | 0.227 | GABA C receptor rho-2 antagonist | 0.227 0.017 DBMET00285 0.187 0.037 DBMET02951 | ||
| 0.212 | 0.004 | 0.212 | Nociceptin (N/OFQ) receptor antagonist | |||
| 0.27 | 0.063 | 0.433 | 5 Hydroxytryptamine uptake stimulant | 0.27 0.063 DBMET00285 0.433 0.009 DBMET02951 | DBMET02951 | |
| 0.218 | 0.011 | 0.218 | Opioid antagonist | |||
| 0.214 | 0.01 | 0.214 | Antineoplastic alkaloid | 0.214 0.01 DBMET00285 | ||
| 0.333 | 0.131 | 0.472 | 5 Hydroxytryptamine release inhibitor | 0.333 0.131 DBMET00285 0.472 0.042 DBMET02951 | DBMET02951 | |
| 0.26 | 0.059 | 0.375 | Tyrosine 3 hydroxylase inhibitor | 0.26 0.059 DBMET00285 0.375 0.011 DBMET02951 | DBMET02951 | |
| 0.272 | 0.079 | 0.537 | 5 Hydroxytryptamine release stimulant | 0.272 0.079 DBMET00285 0.537 0.022 DBMET02951 | DBMET02951 | |
| 0.206 | 0.016 | 0.206 | GABA receptor agonist | 0.173 0.026 DBMET00285 | ||
| 0.196 | 0.009 | 0.196 | Opioid mu receptor antagonist | |||
| 0.196 | 0.01 | 0.196 | Analgesic, opioid | |||
| 0.234 | 0.061 | 0.348 | RNA-directed DNA polymerase inhibitor | 0.348 0.024 DBMET00285 0.225 0.068 DBMET02951 | DBMET00285 | |
| 0.172 | 0.013 | 0.172 | Electrolyte absorption antagonist | 0.149 0.02 DBMET00285 0.121 0.035 DBMET02951 | ||
| 0.192 | 0.043 | 0.192 | MAP kinase kinase 5 inhibitor | 0.176 0.071 DBMET02951 | ||
| 0.211 | 0.071 | 0.211 | Nitric-oxide synthase stimulant | 0.211 0.071 DBMET00285 0.202 0.085 DBMET02951 | ||
| 0.229 | 0.091 | 0.614 | Aldehyde oxidase inhibitor | 0.614 0.017 DBMET00285 0.554 0.025 DBMET02951 | DBMET00285 | |
| 0.257 | 0.122 | 0.257 | Transcription factor NF kappa B inhibitor | 0.223 0.148 DBMET00285 | ||
| 0.175 | 0.043 | 0.305 | Alpha-N-acetylglucosaminidase inhibitor | 0.175 0.043 DBMET00285 0.305 0.016 DBMET02951 | DBMET02951 | |
| 0.214 | 0.086 | 0.214 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.16 | 0.033 | 0.16 | Antiadrenergic | |||
| 0.224 | 0.099 | 0.326 | Interleukin agonist | 0.165 0.153 DBMET00285 0.326 0.037 DBMET02951 | DBMET02951 | |
| 0.152 | 0.029 | 0.218 | GABA C receptor antagonist | 0.152 0.029 DBMET00285 0.218 0.01 DBMET02951 | DBMET02951 | |
| 0.146 | 0.023 | 0.175 | GABA C receptor rho-1 antagonist | 0.146 0.023 DBMET00285 0.175 0.013 DBMET02951 | DBMET02951 | |
| 0.153 | 0.034 | 0.153 | Adrenaline antagonist | |||
| 0.258 | 0.142 | 0.353 | Immunosuppressant | 0.353 0.085 DBMET00285 0.225 0.171 DBMET02951 | DBMET00285 | |
| 0.114 | 0.004 | 0.114 | Nociceptin (N/OFQ) receptor agonist | |||
| 0.212 | 0.105 | 0.303 | DNA synthesis inhibitor | 0.303 0.042 DBMET00285 0.212 0.106 DBMET02951 | DBMET00285 | |
| 0.114 | 0.008 | 0.114 | Phospholipase D inhibitor | 0.091 0.021 DBMET00285 0.086 0.027 DBMET02951 | ||
| 0.279 | 0.175 | 0.297 | Calcium channel L-type activator | 0.279 0.175 DBMET00285 0.297 0.16 DBMET02951 | DBMET02951 | |
| 0.14 | 0.038 | 0.245 | GABA C receptor agonist | 0.14 0.038 DBMET00285 0.245 0.014 DBMET02951 | DBMET02951 | |
| 0.133 | 0.043 | 0.136 | Photosensitizer | 0.133 0.043 DBMET00285 0.136 0.041 DBMET02951 | DBMET02951 | |
| 0.122 | 0.035 | 0.144 | DNA directed RNA polymerase inhibitor | 0.144 0.026 DBMET00285 | DBMET00285 | |
| 0.218 | 0.131 | 0.218 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.183 | 0.098 | 0.206 | 5 Hydroxytryptamine 3E antagonist | 0.183 0.098 DBMET00285 0.206 0.053 DBMET02951 | DBMET02951 | |
| 0.139 | 0.059 | 0.139 | Cholinergic antagonist | |||
| 0.137 | 0.057 | 0.137 | Acetylcholine antagonist | |||
| 0.118 | 0.042 | 0.149 | Anabolic | 0.149 0.019 DBMET00285 0.13 0.031 DBMET02951 | DBMET00285 | |
| 0.152 | 0.076 | 0.19 | Diuretic | 0.19 0.048 DBMET00285 0.157 0.072 DBMET02951 | DBMET00285 | |
| 0.163 | 0.091 | 0.314 | Succinate dehydrogenase inhibitor | 0.163 0.091 DBMET00285 0.314 0.009 DBMET02951 | DBMET02951 | |
| 0.105 | 0.033 | 0.105 | Factor XII inhibitor | 0.08 0.067 DBMET02951 | ||
| 0.087 | 0.016 | 0.087 | Opioid agonist | |||
| 0.079 | 0.009 | 0.098 | Guanylate cyclase stimulant | 0.098 0.006 DBMET00285 | DBMET00285 | |
| 0.124 | 0.055 | 0.124 | Alpha 2b adrenoreceptor antagonist | |||
| 0.111 | 0.045 | 0.283 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.213 0.014 DBMET00285 0.283 0.007 DBMET02951 | DBMET02951 | |
| 0.192 | 0.125 | 0.328 | Immunostimulant | 0.328 0.071 DBMET00285 0.301 0.078 DBMET02951 | DBMET00285 | |
| 0.171 | 0.106 | 0.188 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.155 0.137 DBMET00285 0.188 0.083 DBMET02951 | DBMET02951 | |
| 0.173 | 0.108 | 0.173 | HERG channel blocker | |||
| 0.073 | 0.009 | 0.073 | Glycine transporter 1 inhibitor | |||
| 0.125 | 0.062 | 0.125 | Acetylcholine muscarinic antagonist | 0.111 0.077 DBMET00285 0.114 0.074 DBMET02951 | ||
| 0.094 | 0.031 | 0.094 | Opioid delta receptor antagonist | |||
| 0.112 | 0.05 | 0.112 | Alpha adrenoreceptor antagonist | |||
| 0.109 | 0.052 | 0.202 | UDP-glucose 4-epimerase inhibitor | 0.202 0.018 DBMET00285 0.116 0.046 DBMET02951 | DBMET00285 | |
| 0.094 | 0.038 | 0.117 | Glycine receptor antagonist | 0.117 0.02 DBMET00285 0.112 0.023 DBMET02951 | DBMET00285 | |
| 0.101 | 0.047 | 0.101 | Thioredoxin inhibitor | |||
| 0.113 | 0.063 | 0.113 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.073 | 0.025 | 0.148 | Phosphodiesterase 4C inhibitor | 0.148 0.008 DBMET00285 | DBMET00285 | |
| 0.119 | 0.072 | 0.172 | Aldehyde dehydrogenase inhibitor | 0.172 0.036 DBMET02951 | DBMET02951 | |
| 0.114 | 0.067 | 0.114 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.136 | 0.091 | 0.161 | Ca2+-transporting ATPase inhibitor | 0.136 0.091 DBMET00285 0.161 0.022 DBMET02951 | DBMET02951 | |
| 0.271 | 0.227 | 0.36 | Caspase 9 stimulant | 0.355 0.141 DBMET00285 0.36 0.138 DBMET02951 | DBMET02951 | |
| 0.11 | 0.067 | 0.138 | Acetylcholine release stimulant | 0.128 0.037 DBMET00285 0.138 0.026 DBMET02951 | DBMET02951 | |
| 0.057 | 0.015 | 0.073 | Thymidine kinase inhibitor | 0.073 0.01 DBMET00285 | DBMET00285 | |
| 0.134 | 0.093 | 0.173 | Adenylate cyclase stimulant | 0.142 0.077 DBMET00285 0.173 0.032 DBMET02951 | DBMET02951 | |
| 0.18 | 0.141 | 0.514 | Superoxide dismutase inhibitor | 0.289 0.054 DBMET00285 0.514 0.012 DBMET02951 | DBMET02951 | |
| 0.044 | 0.005 | 0.062 | Guanylate cyclase 1 stimulant | 0.062 0.004 DBMET00285 | DBMET00285 | |
| 0.045 | 0.008 | 0.045 | HCV polyprotein inhibitor | |||
| 0.085 | 0.049 | 0.085 | Acetylcholine nicotinic antagonist | 0.079 0.056 DBMET00285 | ||
| 0.07 | 0.036 | 0.073 | NMDA receptor glycine site agonist | 0.059 0.047 DBMET00285 0.073 0.034 DBMET02951 | DBMET02951 | |
| 0.137 | 0.104 | 0.186 | Arachidonic acid antagonist | 0.143 0.097 DBMET00285 0.186 0.048 DBMET02951 | DBMET02951 | |
| 0.066 | 0.034 | 0.066 | Corticotropin releasing factor 2 receptor antagonist | 0.06 0.047 DBMET00285 0.066 0.034 DBMET02951 | ||
| 0.046 | 0.016 | 0.046 | p53 inhibitor | |||
| 0.08 | 0.049 | 0.08 | Viral attachment inhibitor | |||
| 0.152 | 0.121 | 0.16 | Angiogenesis stimulant | 0.16 0.116 DBMET00285 0.154 0.12 DBMET02951 | DBMET00285 | |
| 0.084 | 0.056 | 0.118 | Estrogen-related receptor beta agonist | 0.084 0.056 DBMET00285 0.118 0.011 DBMET02951 | DBMET02951 | |
| 0.206 | 0.179 | 0.231 | Ca(v)3.3 blocker | 0.229 0.135 DBMET00285 0.231 0.132 DBMET02951 | DBMET02951 | |
| 0.07 | 0.043 | 0.105 | Exportin-1 inhibitor | 0.105 0.007 DBMET02951 | DBMET02951 | |
| 0.053 | 0.026 | 0.073 | Aldosterone antagonist | 0.073 0.013 DBMET00285 | DBMET00285 | |
| 0.065 | 0.039 | 0.1 | NMDA 2C receptor antagonist | 0.1 0.015 DBMET00285 0.07 0.033 DBMET02951 | DBMET00285 | |
| 0.053 | 0.027 | 0.053 | Opioid mu receptor agonist | 0.044 0.035 DBMET02951 | ||
| 0.046 | 0.02 | 0.046 | Substance P antagonist | |||
| 0.156 | 0.13 | 0.249 | Neurotrophic factor enhancer | 0.164 0.118 DBMET00285 0.249 0.039 DBMET02951 | DBMET02951 | |
| 0.204 | 0.178 | 0.276 | Vasodilator, coronary | 0.276 0.108 DBMET00285 0.276 0.109 DBMET02951 | DBMET02951 | |
| 0.033 | 0.01 | 0.08 | Nicotinic acid receptor 2 antagonist | 0.08 0.003 DBMET00285 0.025 0.021 DBMET02951 | DBMET00285 | |
| 0.064 | 0.042 | 0.081 | NMDA receptor agonist | 0.081 0.028 DBMET02951 | DBMET02951 | |
| 0.121 | 0.1 | 0.124 | Mannose-6-phosphate isomerase inhibitor | 0.115 0.11 DBMET00285 0.124 0.094 DBMET02951 | DBMET02951 | |
| 0.061 | 0.04 | 0.106 | Androgen agonist | 0.106 0.013 DBMET00285 | DBMET00285 | |
| 0.06 | 0.04 | 0.162 | Biliverdin reductase inhibitor | 0.117 0.014 DBMET00285 0.162 0.008 DBMET02951 | DBMET02951 | |
| 0.067 | 0.047 | 0.088 | MDM2 inhibitor | 0.088 0.013 DBMET00285 0.075 0.027 DBMET02951 | DBMET00285 | |
| 0.199 | 0.18 | 0.199 | Apoptosis antagonist | |||
| 0.095 | 0.076 | 0.165 | Adenylate kinase inhibitor | 0.107 0.057 DBMET00285 0.165 0.022 DBMET02951 | DBMET02951 | |
| 0.074 | 0.056 | 0.074 | Alpha 1 adrenoreceptor antagonist | |||
| 0.071 | 0.053 | 0.071 | Alpha 1b adrenoreceptor antagonist | |||
| 0.098 | 0.081 | 0.098 | 5 Hydroxytryptamine antagonist | |||
| 0.072 | 0.054 | 0.232 | Porphobilinogen synthase inhibitor | 0.072 0.054 DBMET00285 0.232 0.009 DBMET02951 | DBMET02951 | |
| 0.071 | 0.054 | 0.134 | Metalloproteinase-9 inhibitor | 0.134 0.02 DBMET00285 | DBMET00285 | |
| 0.079 | 0.062 | 0.079 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.196 | 0.181 | 0.344 | Vasodilator, peripheral | 0.306 0.094 DBMET00285 0.344 0.076 DBMET02951 | DBMET02951 | |
| 0.042 | 0.027 | 0.061 | Kainate receptor agonist | 0.06 0.007 DBMET00285 0.061 0.006 DBMET02951 | DBMET02951 | |
| 0.187 | 0.173 | 0.276 | Thyroid hormone antagonist | 0.276 0.107 DBMET00285 | DBMET00285 | |
| 0.135 | 0.12 | 0.135 | Amyloid beta precursor protein antagonist | |||
| 0.023 | 0.009 | 0.039 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.039 0.003 DBMET00285 | DBMET00285 | |
| 0.078 | 0.064 | 0.078 | Phosphodiesterase 11A inhibitor | |||
| 0.078 | 0.064 | 0.078 | Phosphodiesterase XI inhibitor | |||
| 0.188 | 0.176 | 0.316 | Cholesterol antagonist | 0.264 0.115 DBMET00285 0.316 0.081 DBMET02951 | DBMET02951 | |
| 0.028 | 0.016 | 0.042 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.042 0.005 DBMET00285 | DBMET00285 | |
| 0.088 | 0.078 | 0.088 | Alpha 2c adrenoreceptor antagonist | |||
| 0.052 | 0.042 | 0.076 | Matrix metalloproteinase (membrane-type) inhibitor | 0.076 0.021 DBMET00285 | DBMET00285 | |
| 0.115 | 0.105 | 0.326 | Peroxidase inhibitor | 0.145 0.08 DBMET00285 0.326 0.032 DBMET02951 | DBMET02951 | |
| 0.115 | 0.106 | 0.177 | Cytidine deaminase inhibitor | 0.177 0.058 DBMET00285 | DBMET00285 | |
| 0.095 | 0.086 | 0.138 | DOPA decarboxylase inhibitor | 0.095 0.086 DBMET00285 0.138 0.029 DBMET02951 | DBMET02951 | |
| 0.058 | 0.049 | 0.058 | 5 Hydroxytryptamine 2A agonist | |||
| 0.081 | 0.072 | 0.11 | Granulocyte macrophage colony stimulating factor agonist | 0.081 0.072 DBMET00285 0.11 0.024 DBMET02951 | DBMET02951 | |
| 0.071 | 0.064 | 0.134 | Metalloproteinase-2 inhibitor | 0.134 0.024 DBMET00285 | DBMET00285 | |
| 0.083 | 0.076 | 0.164 | Prolactin inhibitor | 0.095 0.061 DBMET00285 0.164 0.017 DBMET02951 | DBMET02951 | |
| 0.081 | 0.075 | 0.178 | Triose-phosphate isomerase inhibitor | 0.085 0.068 DBMET00285 0.178 0.014 DBMET02951 | DBMET02951 | |
| 0.037 | 0.033 | 0.058 | Dopamine D5 agonist | 0.037 0.033 DBMET00285 0.058 0.013 DBMET02951 | DBMET02951 | |
| 0.086 | 0.083 | 0.09 | Alpha 2d adrenoreceptor antagonist | 0.09 0.07 DBMET00285 | DBMET00285 | |
| 0.12 | 0.117 | 0.12 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.057 | 0.054 | 0.089 | Neutrophil collagenase inhibitor | 0.089 0.027 DBMET00285 | DBMET00285 | |
| 0.053 | 0.051 | 0.067 | Pregnane X receptor antagonist | 0.067 0.018 DBMET00285 0.063 0.024 DBMET02951 | DBMET00285 | |
| 0.029 | 0.027 | 0.029 | Prostacyclin antagonist | |||
| 0.097 | 0.096 | 0.108 | Microtubule formation inhibitor | 0.097 0.096 DBMET00285 0.108 0.077 DBMET02951 | DBMET02951 | |
| 0.047 | 0.046 | 0.191 | Acyl-CoA dehydrogenase inhibitor | 0.047 0.046 DBMET00285 0.191 0.006 DBMET02951 | DBMET02951 | |
| 0.169 | 0.168 | 0.221 | 5 Hydroxytryptamine 1E antagonist | 0.221 0.108 DBMET00285 0.205 0.126 DBMET02951 | DBMET00285 | |
| 0.062 | 0.061 | 0.062 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.023 | 0.022 | 0.03 | Lysophosphatidic acid receptor 1 agonist | 0.023 0.022 DBMET00285 0.03 0.011 DBMET02951 | DBMET02951 | |
| 0.09 | 0.09 | 0.142 | 5 Hydroxytryptamine 3A agonist | 0.142 0.04 DBMET00285 0.09 0.089 DBMET02951 | DBMET00285 | |
| 0.006 | 0.008 | 0.018 | DNA topoisomerase III inhibitor | 0.018 0.002 DBMET00285 | DBMET00285 | |
| 0.038 | 0.04 | 0.049 | Glycine transporter 2 inhibitor | 0.049 0.031 DBMET02951 | DBMET02951 | |
| 0.044 | 0.046 | 0.061 | Lysophosphatidic acid 3 receptor antagonist | 0.061 0.022 DBMET02951 | DBMET02951 | |
| 0.081 | 0.085 | 0.197 | Creatine kinase inhibitor | 0.197 0.011 DBMET02951 | DBMET02951 | |
| 0.039 | 0.044 | 0.055 | Histamine H1 receptor agonist | 0.055 0.013 DBMET02951 | DBMET02951 | |
| 0.039 | 0.045 | 0.053 | Adenylate cyclase 1 inhibitor | 0.053 0.024 DBMET00285 0.045 0.033 DBMET02951 | DBMET00285 | |
| 0.046 | 0.052 | 0.312 | Alcohol oxidase inhibitor | 0.059 0.036 DBMET00285 0.312 0.004 DBMET02951 | DBMET02951 | |
| 0.054 | 0.061 | 0.104 | Matrix metalloproteinase inhibitor | 0.104 0.025 DBMET00285 | DBMET00285 | |
| 0.177 | 0.184 | 0.253 | Gastrin inhibitor | 0.232 0.102 DBMET00285 0.253 0.076 DBMET02951 | DBMET02951 | |
| 0.076 | 0.083 | 0.113 | NADH dehydrogenase inhibitor | 0.113 0.033 DBMET00285 0.094 0.051 DBMET02951 | DBMET00285 | |
| 0.021 | 0.028 | 0.07 | Uridine phosphorylase inhibitor | 0.07 0.004 DBMET00285 0.037 0.013 DBMET02951 | DBMET00285 | |
| 0.038 | 0.046 | 0.065 | Matrix metalloproteinase 1 inhibitor | 0.065 0.029 DBMET00285 | DBMET00285 | |
| 0.033 | 0.041 | 0.054 | Membrane dipeptidase inhibitor | 0.038 0.029 DBMET00285 0.054 0.013 DBMET02951 | DBMET02951 | |
| 0.04 | 0.048 | 0.055 | Mineralocorticoid receptor antagonist | 0.055 0.024 DBMET00285 | DBMET00285 | |
| 0.06 | 0.069 | 0.144 | Aminopeptidase I inhibitor | 0.144 0.013 DBMET02951 | DBMET02951 | |
| 0.104 | 0.114 | 0.163 | Protein kinase stimulant | 0.163 0.06 DBMET00285 0.142 0.074 DBMET02951 | DBMET00285 | |
| 0.008 | 0.02 | 0.014 | Lysophosphatidic acid receptor 3 agonist | 0.014 0.009 DBMET02951 | DBMET02951 | |
| 0.055 | 0.066 | 0.097 | Phenylalanine 4-hydroxylase inhibitor | 0.097 0.027 DBMET02951 | DBMET02951 | |
| 0.036 | 0.048 | 0.04 | GABA B receptor antagonist | 0.04 0.036 DBMET02951 | DBMET02951 | |
| 0.192 | 0.204 | 0.277 | Interleukin 2 agonist | 0.277 0.092 DBMET02951 | DBMET02951 | |
| 0.044 | 0.056 | 0.11 | Argininosuccinate synthase inhibitor | 0.086 0.023 DBMET00285 0.11 0.017 DBMET02951 | DBMET02951 | |
| 0.047 | 0.061 | 0.088 | Dihydroorotate oxidase inhibitor | 0.088 0.008 DBMET00285 0.057 0.034 DBMET02951 | DBMET00285 | |
| 0.021 | 0.036 | 0.041 | Thymidine phosphorylase inhibitor | 0.041 0.006 DBMET00285 0.024 0.023 DBMET02951 | DBMET00285 | |
| 0.052 | 0.067 | 0.103 | Phosphodiesterase 1A inhibitor | 0.103 0.009 DBMET00285 | DBMET00285 | |
| 0.031 | 0.046 | 0.039 | Potassium channel Kv1.1 blocker | 0.039 0.025 DBMET00285 0.037 0.027 DBMET02951 | DBMET00285 | |
| 0.047 | 0.064 | 0.092 | Collagenase 3 inhibitor | 0.092 0.018 DBMET00285 | DBMET00285 | |
| 0.049 | 0.067 | 0.097 | Immunoglobulin Fc receptor antagonist | 0.097 0.004 DBMET02951 | DBMET02951 | |
| 0.06 | 0.079 | 0.109 | Glycine receptor agonist | 0.08 0.038 DBMET00285 0.109 0.016 DBMET02951 | DBMET02951 | |
| 0.082 | 0.101 | 0.111 | Carbonic anhydrase XV inhibitor | 0.111 0.055 DBMET02951 | DBMET02951 | |
| 0.034 | 0.054 | 0.084 | NMDA 2A receptor antagonist | 0.084 0.018 DBMET00285 | DBMET00285 | |
| 0.043 | 0.064 | 0.074 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.074 0.023 DBMET00285 | DBMET00285 | |
| 0.039 | 0.061 | 0.056 | Dopamine beta hydroxylase inhibitor | 0.056 0.02 DBMET02951 | DBMET02951 | |
| 0.014 | 0.036 | 0.018 | Methylmalonyl-CoA mutase inhibitor | 0.018 0.012 DBMET02951 | DBMET02951 | |
| 0.038 | 0.06 | 0.052 | Parathyroid hormone antagonist | 0.052 0.018 DBMET00285 | DBMET00285 | |
| 0.057 | 0.08 | 0.091 | Glutamate (mGluR6) antagonist | 0.064 0.055 DBMET00285 0.091 0.015 DBMET02951 | DBMET02951 | |
| 0.029 | 0.054 | 0.04 | Tryptophan 5 hydroxylase inhibitor | 0.04 0.016 DBMET00285 | DBMET00285 | |
| 0.043 | 0.068 | 0.093 | Carbamoyl phosphate synthetase inhibitor | 0.059 0.043 DBMET00285 0.093 0.023 DBMET02951 | DBMET02951 | |
| 0.061 | 0.087 | 0.092 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.092 0.02 DBMET02951 | DBMET02951 | |
| 0.055 | 0.081 | 0.082 | Glutamate (mGluR7) antagonist | 0.063 0.056 DBMET00285 0.082 0.025 DBMET02951 | DBMET02951 | |
| 0.016 | 0.043 | 0.03 | Prostaglandin EP3 antagonist | 0.03 0.021 DBMET00285 | DBMET00285 | |
| 0.015 | 0.043 | 0.02 | Retinoid X beta receptor antagonist | 0.02 0.016 DBMET02951 | DBMET02951 | |
| 0.021 | 0.05 | 0.061 | Fumarate hydratase inhibitor | 0.034 0.024 DBMET00285 0.061 0.01 DBMET02951 | DBMET02951 | |
| 0.025 | 0.055 | 0.035 | Melatonin receptor 1A agonist | 0.035 0.02 DBMET02951 | DBMET02951 | |
| 0.019 | 0.05 | 0.033 | Acid ceramidase inhibitor | 0.033 0.007 DBMET00285 | DBMET00285 | |
| 0.092 | 0.124 | 0.237 | Cathepsin H inhibitor | 0.237 0.015 DBMET02951 | DBMET02951 | |
| 0.067 | 0.099 | 0.169 | Aminopeptidase B inhibitor | 0.169 0.03 DBMET02951 | DBMET02951 | |
| 0.051 | 0.085 | 0.167 | Protein kinase C alpha inhibitor | 0.167 0.008 DBMET02951 | DBMET02951 | |
| 0.055 | 0.089 | 0.151 | Glutamate dehydrogenase inhibitor | 0.151 0.015 DBMET02951 | DBMET02951 | |
| 0.026 | 0.061 | 0.041 | GABA uptake inhibitor | 0.041 0.024 DBMET02951 | DBMET02951 | |
| 0.044 | 0.08 | 0.1 | Phosphofructokinase-1 inhibitor | 0.075 0.044 DBMET00285 0.1 0.032 DBMET02951 | DBMET02951 | |
| 0.01 | 0.047 | 0.016 | DNA polymerase III polC-type inhibitor | 0.016 0.005 DBMET00285 | DBMET00285 | |
| 0.017 | 0.055 | 0.04 | Retinoid X receptor agonist | 0.04 0.023 DBMET02951 | DBMET02951 | |
| 0.024 | 0.063 | 0.06 | Oxytocin agonist | 0.06 0.017 DBMET02951 | DBMET02951 | |
| 0.006 | 0.045 | 0.013 | Carbonic anhydrase XI inhibitor | 0.013 0.008 DBMET02951 | DBMET02951 | |
| 0.061 | 0.1 | 0.087 | Vanilloid 4 agonist | 0.087 0.029 DBMET02951 | DBMET02951 | |
| 0.036 | 0.076 | 0.079 | Aconitate hydratase inhibitor | 0.079 0.014 DBMET02951 | DBMET02951 | |
| 0.087 | 0.127 | 0.141 | Cyclooxygenase 3 inhibitor | 0.141 0.056 DBMET02951 | DBMET02951 | |
| 0.028 | 0.068 | 0.061 | Histamine H2 receptor agonist | 0.061 0.014 DBMET02951 | DBMET02951 | |
| 0.01 | 0.051 | 0.016 | Telomerase stimulant | 0.016 0.013 DBMET02951 | DBMET02951 | |
| 0.007 | 0.05 | 0.032 | Carbonic anhydrase X inhibitor | 0.032 0.004 DBMET02951 | DBMET02951 | |
| 0.007 | 0.05 | 0.032 | Carbonic anhydrase VIII inhibitor | 0.032 0.004 DBMET02951 | DBMET02951 | |
| 0.047 | 0.09 | 0.102 | Protease 3C (Human rhinovirus) inhibitor | 0.102 0.015 DBMET02951 | DBMET02951 | |
| 0.039 | 0.083 | 0.061 | TRPA1 antagonist | 0.061 0.041 DBMET00285 | DBMET00285 | |
| 0.054 | 0.1 | 0.108 | GABA aminotransferase inhibitor | 0.108 0.022 DBMET02951 | DBMET02951 | |
| 0.033 | 0.081 | 0.051 | Glucose-6-phosphate isomerase inhibitor | 0.051 0.028 DBMET02951 | DBMET02951 | |
| 0.03 | 0.078 | 0.047 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.047 0.019 DBMET02951 | DBMET02951 | |
| 0.126 | 0.175 | 0.186 | Neurotensin receptor agonist | 0.164 0.072 DBMET00285 0.186 0.044 DBMET02951 | DBMET02951 | |
| 0.026 | 0.076 | 0.046 | Glutamate (mGluR8) agonist | 0.046 0.015 DBMET02951 | DBMET02951 | |
| 0.016 | 0.067 | 0.026 | Vanilloid 2 agonist | 0.026 0.015 DBMET02951 | DBMET02951 | |
| 0.047 | 0.099 | 0.14 | Glutamate decarboxylase inhibitor | 0.14 0.015 DBMET02951 | DBMET02951 | |
| 0.013 | 0.065 | 0.025 | Neuraminidase (Influenza B) inhibitor | 0.025 0.008 DBMET02951 | DBMET02951 | |
| 0.018 | 0.07 | 0.048 | Retinoid X alpha receptor agonist | 0.048 0.015 DBMET02951 | DBMET02951 | |
| 0.016 | 0.069 | 0.028 | Glutamate (mGluR1) agonist | 0.024 0.018 DBMET00285 0.028 0.012 DBMET02951 | DBMET02951 | |
| 0.02 | 0.073 | 0.035 | Melanocortin 1 antagonist | 0.035 0.03 DBMET02951 | DBMET02951 | |
| 0.006 | 0.062 | 0.016 | Aminopeptidase A inhibitor | 0.016 0.014 DBMET02951 | DBMET02951 | |
| 0.022 | 0.079 | 0.041 | Retinoid X alpha receptor antagonist | 0.041 0.014 DBMET02951 | DBMET02951 | |
| 0.01 | 0.067 | 0.021 | Estrogen-related receptor gamma agonist | 0.021 0.009 DBMET02951 | DBMET02951 | |
| 0.037 | 0.093 | 0.082 | Carbonic anhydrase stimulant | 0.082 0.025 DBMET02951 | DBMET02951 | |
| 0.017 | 0.075 | 0.032 | Epoxide hydrolase 1 inhibitor | 0.032 0.019 DBMET02951 | DBMET02951 | |
| 0.034 | 0.092 | 0.07 | Alpha-mannosidase inhibitor | 0.07 0.017 DBMET02951 | DBMET02951 | |
| 0.036 | 0.095 | 0.056 | Acetylcholine M5 receptor antagonist | 0.056 0.048 DBMET02951 | DBMET02951 | |
| 0.111 | 0.17 | 0.157 | CF transmembrane conductance regulator agonist | 0.133 0.112 DBMET00285 0.157 0.065 DBMET02951 | DBMET02951 | |
| 0.176 | 0.235 | 0.394 | Histamine release inhibitor | 0.273 0.14 DBMET00285 0.394 0.079 DBMET02951 | DBMET02951 | |
| 0.097 | 0.158 | 0.195 | Vanilloid 1 agonist | 0.195 0.013 DBMET02951 | DBMET02951 | |
| 0.052 | 0.113 | 0.085 | Androgen antagonist | 0.085 0.06 DBMET00285 | DBMET00285 | |
| 0.024 | 0.085 | 0.046 | Retinoid X receptor antagonist | 0.046 0.016 DBMET02951 | DBMET02951 | |
| 0.093 | 0.155 | 0.129 | Acetylcholine M1 receptor antagonist | 0.129 0.097 DBMET02951 | DBMET02951 | |
| 0.025 | 0.088 | 0.055 | AMPA 4 receptor antagonist | 0.055 0.012 DBMET02951 | DBMET02951 | |
| 0.054 | 0.117 | 0.1 | Keratolytic | 0.1 0.03 DBMET00285 0.083 0.045 DBMET02951 | DBMET00285 | |
| 0.017 | 0.08 | 0.032 | Purinergic P2Y15 antagonist | 0.032 0.013 DBMET02951 | DBMET02951 | |
| 0.162 | 0.226 | 0.297 | Insulysin inhibitor | 0.202 0.154 DBMET00285 0.297 0.061 DBMET02951 | DBMET02951 | |
| 0.005 | 0.069 | 0.013 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.013 0.009 DBMET02951 | DBMET02951 | |
| 0.068 | 0.132 | 0.101 | CC chemokine 5 receptor agonist | 0.101 0.021 DBMET02951 | DBMET02951 | |
| 0.012 | 0.077 | 0.036 | Glucocorticoid antagonist | 0.036 0.02 DBMET00285 | DBMET00285 | |
| 0.01 | 0.075 | 0.025 | Glutamate (mGluR1a) agonist | 0.025 0.012 DBMET02951 | DBMET02951 | |
| 0.007 | 0.073 | 0.016 | Nicotinic acid receptor 1 antagonist | 0.016 0.015 DBMET02951 | DBMET02951 | |
| 0.023 | 0.09 | 0.095 | Ornithine carbamoyltransferase inhibitor | 0.095 0.017 DBMET02951 | DBMET02951 | |
| 0.04 | 0.107 | 0.071 | Histidine decarboxylase inhibitor | 0.071 0.05 DBMET02951 | DBMET02951 | |
| 0.105 | 0.174 | 0.205 | Sphingosine 1-phosphate receptor 5 antagonist | 0.133 0.094 DBMET00285 0.205 0.009 DBMET02951 | DBMET02951 | |
| 0.104 | 0.174 | 0.168 | Melanin inhibitor | 0.168 0.061 DBMET02951 | DBMET02951 | |
| 0.017 | 0.089 | 0.027 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.027 0.02 DBMET02951 | DBMET02951 | |
| 0.057 | 0.13 | 0.127 | HIV-1 integrase (Overall Integration) inhibitor | 0.127 0.035 DBMET00285 0.114 0.043 DBMET02951 | DBMET00285 | |
| 0.014 | 0.087 | 0.077 | Nicotinic acid receptor agonist | 0.077 0.007 DBMET00285 | DBMET00285 | |
| 0.011 | 0.086 | 0.018 | Caspase 8 inhibitor | 0.018 0.017 DBMET02951 | DBMET02951 | |
| 0.068 | 0.143 | 0.111 | Proteasome inhibitor | 0.111 0.073 DBMET02951 | DBMET02951 | |
| 0.064 | 0.14 | 0.099 | Cystathionine beta-synthase inhibitor | 0.099 0.077 DBMET00285 0.09 0.089 DBMET02951 | DBMET00285 | |
| 0.04 | 0.115 | 0.105 | Potassium channel intermediate-conductance Ca-activated blocker | 0.105 0.008 DBMET02951 | DBMET02951 | |
| 0.018 | 0.094 | 0.036 | DNA polymerase III inhibitor | 0.036 0.007 DBMET00285 | DBMET00285 | |
| 0.018 | 0.095 | 0.027 | Hedgehog signaling activator | 0.027 0.019 DBMET02951 | DBMET02951 | |
| 0.021 | 0.098 | 0.033 | Glutamate (mGluR3) agonist | 0.033 0.02 DBMET02951 | DBMET02951 | |
| 0.017 | 0.094 | 0.046 | Vascular adhesion protein 1 inhibitor | 0.046 0.018 DBMET02951 | DBMET02951 | |
| 0.022 | 0.1 | 0.057 | Mannosidase inhibitor | 0.057 0.019 DBMET02951 | DBMET02951 | |
| 0.039 | 0.118 | 0.157 | Phosphodiesterase 4D inhibitor | 0.157 0.018 DBMET00285 | DBMET00285 | |
| 0.043 | 0.123 | 0.065 | Interferon inducer | 0.065 0.044 DBMET02951 | DBMET02951 | |
| 0.087 | 0.167 | 0.197 | Sphingosine 1-phosphate receptor 4 antagonist | 0.197 0.009 DBMET02951 | DBMET02951 | |
| 0.021 | 0.101 | 0.061 | Delayed rectifier potassium channel blocker | 0.061 0.007 DBMET02951 | DBMET02951 | |
| 0.036 | 0.117 | 0.181 | Catalase inhibitor | 0.181 0.019 DBMET02951 | DBMET02951 | |
| 0.103 | 0.186 | 0.154 | Interferon gamma antagonist | 0.154 0.073 DBMET02951 | DBMET02951 | |
| 0.062 | 0.146 | 0.094 | Lanosterol 14 alpha demethylase inhibitor | 0.094 0.065 DBMET02951 | DBMET02951 | |
| 0.055 | 0.14 | 0.108 | GABA B receptor agonist | 0.108 0.012 DBMET02951 | DBMET02951 | |
| 0.01 | 0.095 | 0.024 | Protease (Human cytomegalovirus) inhibitor | 0.024 0.012 DBMET02951 | DBMET02951 | |
| 0.037 | 0.123 | 0.074 | Na+ K+ transporting ATPase inhibitor | 0.074 0.056 DBMET02951 | DBMET02951 | |
| 0.047 | 0.133 | 0.078 | Myeloperoxidase inhibitor | 0.078 0.07 DBMET02951 | DBMET02951 | |
| 0.034 | 0.12 | 0.071 | Bombesin 1 receptor agonist | 0.071 0.03 DBMET02951 | DBMET02951 | |
| 0.013 | 0.101 | 0.028 | Peptide deformylase inhibitor | 0.028 0.024 DBMET02951 | DBMET02951 | |
| 0.031 | 0.119 | 0.083 | Sphingosine 1-phosphate receptor 3 antagonist | 0.083 0.015 DBMET02951 | DBMET02951 | |
| 0.062 | 0.15 | 0.086 | D-Ala-D-Ala ligase inhibitor | 0.086 0.052 DBMET02951 | DBMET02951 | |
| 0.114 | 0.203 | 0.236 | Phospholipase C inhibitor | 0.236 0.028 DBMET02951 | DBMET02951 | |
| 0.074 | 0.163 | 0.163 | TRPA1 agonist | 0.163 0.023 DBMET02951 | DBMET02951 | |
| 0.02 | 0.111 | 0.046 | Geranyltranstransferase inhibitor | 0.046 0.027 DBMET02951 | DBMET02951 | |
| 0.092 | 0.186 | 0.161 | Sphingosine 1-phosphate receptor 2 antagonist | 0.125 0.086 DBMET00285 0.161 0.028 DBMET02951 | DBMET02951 | |
| 0.036 | 0.129 | 0.056 | Purinergic P2X1 antagonist | 0.056 0.049 DBMET02951 | DBMET02951 | |
| 0.032 | 0.126 | 0.062 | Bombesin 3 receptor antagonist | 0.062 0.031 DBMET02951 | DBMET02951 | |
| 0.042 | 0.136 | 0.059 | Ryanodine receptor antagonist | 0.059 0.041 DBMET00285 | DBMET00285 | |
| 0.028 | 0.122 | 0.061 | Acetylcholine M5 receptor agonist | 0.061 0.054 DBMET00285 | DBMET00285 | |
| 0.045 | 0.14 | 0.08 | Histone deacetylase SIRT3 inhibitor | 0.08 0.018 DBMET02951 | DBMET02951 | |
| 0.027 | 0.123 | 0.047 | Glutamate (mGluR4) antagonist | 0.047 0.024 DBMET02951 | DBMET02951 | |
| 0.094 | 0.19 | 0.112 | Papain-like protease (SARS coronavirus) inhibitor | 0.112 0.105 DBMET02951 | DBMET02951 | |
| 0.043 | 0.139 | 0.122 | Ornithine decarboxylase inhibitor | 0.122 0.025 DBMET02951 | DBMET02951 | |
| 0.04 | 0.138 | 0.073 | CYP2A6 inhibitor | 0.073 0.055 DBMET02951 | DBMET02951 | |
| 0.068 | 0.166 | 0.101 | Glutamate (mGluR7) agonist | 0.101 0.058 DBMET02951 | DBMET02951 | |
| 0.018 | 0.119 | 0.042 | Potassium channel Kv1.3 blocker | 0.042 0.04 DBMET02951 | DBMET02951 | |
| 0.013 | 0.114 | 0.029 | Retinoid X gamma receptor antagonist | 0.029 0.015 DBMET02951 | DBMET02951 | |
| 0.106 | 0.207 | 0.16 | 3C-like protease (Human coronavirus) inhibitor | 0.14 0.12 DBMET00285 0.16 0.086 DBMET02951 | DBMET02951 | |
| 0.018 | 0.12 | 0.031 | Carboxypeptidase B inhibitor | 0.031 0.028 DBMET02951 | DBMET02951 | |
| 0.05 | 0.154 | 0.146 | Bronchodilator | 0.146 0.033 DBMET00285 | DBMET00285 | |
| 0.03 | 0.133 | 0.059 | Cannabinoid CB1 receptor antagonist | 0.059 0.046 DBMET02951 | DBMET02951 | |
| 0.04 | 0.144 | 0.054 | Leukotriene C antagonist | 0.054 0.047 DBMET02951 | DBMET02951 | |
| 0.036 | 0.141 | 0.097 | Cathepsin G inhibitor | 0.097 0.034 DBMET02951 | DBMET02951 | |
| 0.012 | 0.118 | 0.026 | Thyroid hormone agonist | 0.026 0.018 DBMET00285 | DBMET00285 | |
| 0.053 | 0.16 | 0.183 | Anesthetic local | 0.183 0.037 DBMET02951 | DBMET02951 | |
| 0.018 | 0.124 | 0.05 | Adenosine deaminase inhibitor | 0.05 0.03 DBMET02951 | DBMET02951 | |
| 0.042 | 0.149 | 0.075 | NMDA receptor antagonist | 0.075 0.072 DBMET00285 | DBMET00285 | |
| 0.044 | 0.152 | 0.077 | Interferon agonist | 0.077 0.057 DBMET02951 | DBMET02951 | |
| 0.026 | 0.134 | 0.067 | Acetyl-CoA transferase inhibitor | 0.067 0.026 DBMET02951 | DBMET02951 | |
| 0.066 | 0.177 | 0.099 | Phosphodiesterase 6D inhibitor | 0.099 0.054 DBMET00285 | DBMET00285 | |
| 0.057 | 0.168 | 0.094 | Bile acid receptor antagonist | 0.094 0.064 DBMET02951 | DBMET02951 | |
| 0.03 | 0.143 | 0.049 | Bombesin 2 receptor antagonist | 0.049 0.035 DBMET02951 | DBMET02951 | |
| 0.047 | 0.161 | 0.063 | Calcium channel P-type blocker | 0.063 0.045 DBMET02951 | DBMET02951 | |
| 0.046 | 0.16 | 0.098 | Urease inhibitor | 0.098 0.069 DBMET02951 | DBMET02951 | |
| 0.042 | 0.157 | 0.101 | Histamine N-methyltransferase inhibitor | 0.101 0.045 DBMET02951 | DBMET02951 | |
| 0.015 | 0.131 | 0.053 | Toll-Like receptor 2 agonist | 0.053 0.022 DBMET02951 | DBMET02951 | |
| 0.115 | 0.231 | 0.313 | Cardiotonic | 0.313 0.051 DBMET00285 0.271 0.069 DBMET02951 | DBMET00285 | |
| 0.018 | 0.135 | 0.047 | Thymidylate synthase inhibitor | 0.047 0.032 DBMET00285 | DBMET00285 | |
| 0.115 | 0.232 | 0.133 | Heat shock protein 70 antagonist | 0.133 0.108 DBMET02951 | DBMET02951 | |
| 0.026 | 0.144 | 0.043 | Glutamate (mGluR group III) antagonist | 0.043 0.031 DBMET02951 | DBMET02951 | |
| 0.048 | 0.167 | 0.144 | Sphingomyelinase inhibitor | 0.144 0.027 DBMET02951 | DBMET02951 | |
| 0.011 | 0.13 | 0.019 | Factor XIII inhibitor | 0.019 0.018 DBMET02951 | DBMET02951 | |
| 0.014 | 0.135 | 0.033 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.033 0.026 DBMET02951 | DBMET02951 | |
| 0.079 | 0.202 | 0.235 | Phospholipase A2 inhibitor | 0.235 0.027 DBMET02951 | DBMET02951 | |
| 0.043 | 0.168 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.053 DBMET02951 | DBMET02951 | |
| 0.058 | 0.186 | 0.12 | Mucolytic | 0.12 0.055 DBMET02951 | DBMET02951 | |
| 0.018 | 0.146 | 0.041 | Glutamate (mGluR1a) antagonist | 0.041 0.029 DBMET02951 | DBMET02951 | |
| 0.016 | 0.145 | 0.037 | Glutamate (mGluR3) antagonist | 0.037 0.024 DBMET02951 | DBMET02951 | |
| 0.05 | 0.181 | 0.119 | Phosphodiesterase I inhibitor | 0.119 0.027 DBMET00285 | DBMET00285 | |
| 0.025 | 0.156 | 0.051 | Leukotriene B4 antagonist | 0.051 0.043 DBMET02951 | DBMET02951 | |
| 0.025 | 0.163 | 0.048 | Cytokine production stimulant | 0.048 0.034 DBMET02951 | DBMET02951 | |
| 0.027 | 0.165 | 0.054 | Squalene epoxidase inhibitor | 0.054 0.028 DBMET02951 | DBMET02951 | |
| 0.008 | 0.147 | 0.023 | Isoleucine-tRNA ligase inhibitor | 0.023 0.014 DBMET02951 | DBMET02951 | |
| 0.026 | 0.165 | 0.069 | Sphingosine 1-phosphate receptor 4 agonist | 0.069 0.045 DBMET02951 | DBMET02951 | |
| 0.016 | 0.158 | 0.043 | Phosphodiesterase 4A inhibitor | 0.043 0.04 DBMET00285 | DBMET00285 | |
| 0.02 | 0.162 | 0.039 | Plasmepsin II inhibitor | 0.039 0.032 DBMET02951 | DBMET02951 | |
| 0.027 | 0.169 | 0.063 | Sphingosine kinase 2 inhibitor | 0.063 0.028 DBMET02951 | DBMET02951 | |
| 0.033 | 0.176 | 0.081 | Calcium antagonist | 0.081 0.062 DBMET02951 | DBMET02951 | |
| 0.019 | 0.164 | 0.047 | Sphingosine kinase 1 inhibitor | 0.047 0.02 DBMET02951 | DBMET02951 | |
| 0.028 | 0.174 | 0.071 | Sphingosine kinase inhibitor | 0.071 0.023 DBMET02951 | DBMET02951 | |
| 0.054 | 0.201 | 0.109 | AMP-activated protein kinase stimulant | 0.109 0.06 DBMET00285 | DBMET00285 | |
| 0.107 | 0.256 | 0.316 | Cyclic AMP phosphodiesterase inhibitor | 0.316 0.036 DBMET00285 | DBMET00285 | |
| 0.088 | 0.237 | 0.263 | Tumour necrosis factor antagonist | 0.263 0.027 DBMET00285 0.159 0.09 DBMET02951 | DBMET00285 | |
| 0.041 | 0.194 | 0.104 | Falcipain 3 inhibitor | 0.104 0.066 DBMET02951 | DBMET02951 | |
| 0.06 | 0.217 | 0.136 | Glutamate release inhibitor | 0.136 0.014 DBMET02951 | DBMET02951 | |
| 0.072 | 0.23 | 0.141 | Cell wall synthesis inhibitor | 0.141 0.074 DBMET02951 | DBMET02951 | |
| 0.089 | 0.248 | 0.138 | Pregnane X receptor agonist | 0.138 0.077 DBMET02951 | DBMET02951 | |
| 0.092 | 0.251 | 0.261 | Tumour necrosis factor alpha release inhibitor | 0.261 0.07 DBMET00285 | DBMET00285 | |
| 0.041 | 0.202 | 0.208 | Protein kinase C delta inhibitor | 0.208 0.008 DBMET02951 | DBMET02951 | |
| 0.061 | 0.222 | 0.16 | Toll-Like receptor 2 antagonist | 0.16 0.046 DBMET02951 | DBMET02951 | |
| 0.015 | 0.177 | 0.052 | Cathepsin L inhibitor | 0.052 0.048 DBMET02951 | DBMET02951 | |
| 0.013 | 0.175 | 0.026 | Thrombin receptor antagonist | 0.026 0.024 DBMET02951 | DBMET02951 | |
| 0.006 | 0.169 | 0.022 | Thyroid hormone alpha agonist | 0.022 0.005 DBMET00285 | DBMET00285 | |
| 0.035 | 0.2 | 0.083 | Somatostatin 1 agonist | 0.083 0.048 DBMET02951 | DBMET02951 | |
| 0.078 | 0.244 | 0.176 | Insulin sensitizer | 0.176 0.1 DBMET02951 | DBMET02951 | |
| 0.02 | 0.189 | 0.037 | Adenosine uptake inhibitor | 0.037 0.017 DBMET02951 | DBMET02951 | |
| 0.123 | 0.293 | 0.272 | Neuropeptide Y2 antagonist | 0.272 0.037 DBMET02951 | DBMET02951 | |
| 0.009 | 0.18 | 0.055 | Ribonucleotide reductase inhibitor | 0.055 0.039 DBMET02951 | DBMET02951 | |
| 0.01 | 0.181 | 0.054 | Ribonucleoside-diphosphate reductase inhibitor | 0.054 0.038 DBMET02951 | DBMET02951 | |
| 0.036 | 0.209 | 0.066 | Phosphodiesterase 1C inhibitor | 0.066 0.035 DBMET00285 | DBMET00285 | |
| 0.017 | 0.191 | 0.035 | Protein kinase (CK2) beta inhibitor | 0.035 0.019 DBMET00285 | DBMET00285 | |
| 0.039 | 0.215 | 0.094 | Expectorant | 0.094 0.076 DBMET02951 | DBMET02951 | |
| 0.028 | 0.206 | 0.044 | Phosphodiesterase 6C inhibitor | 0.044 0.04 DBMET00285 | DBMET00285 | |
| 0.048 | 0.227 | 0.105 | Carbonic anhydrase III inhibitor | 0.105 0.057 DBMET02951 | DBMET02951 | |
| 0.008 | 0.192 | 0.052 | Diamine oxidase inhibitor | 0.052 0.013 DBMET02951 | DBMET02951 | |
| 0.07 | 0.26 | 0.13 | Hexokinase inhibitor | 0.13 0.103 DBMET02951 | DBMET02951 | |
| 0.046 | 0.238 | 0.08 | Bromodomain-containing protein 2 inhibitor | 0.08 0.078 DBMET00285 | DBMET00285 | |
| 0.027 | 0.228 | 0.051 | CD45 antagonist | 0.051 0.033 DBMET02951 | DBMET02951 | |
| 0.009 | 0.21 | 0.031 | Gonadotropin-releasing hormone receptor antagonist | 0.031 0.027 DBMET02951 | DBMET02951 | |
| 0.047 | 0.248 | 0.138 | Adenylate cyclase inhibitor | 0.122 0.065 DBMET00285 0.138 0.053 DBMET02951 | DBMET02951 | |
| 0.031 | 0.234 | 0.097 | Alcohol dehydrogenase inhibitor | 0.091 0.063 DBMET00285 0.097 0.055 DBMET02951 | DBMET02951 | |
| 0.006 | 0.212 | 0.049 | Kinesin-like protein 1 inhibitor | 0.049 0.017 DBMET02951 | DBMET02951 | |
| 0.006 | 0.212 | 0.049 | Kinesin antagonist | 0.049 0.017 DBMET02951 | DBMET02951 | |
| 0.095 | 0.303 | 0.147 | Death-associated protein kinase 2 inhibitor | 0.147 0.114 DBMET02951 | DBMET02951 | |
| 0.065 | 0.276 | 0.136 | Transcription factor STAT6 inhibitor | 0.136 0.037 DBMET02951 | DBMET02951 | |
| 0.044 | 0.257 | 0.097 | DNA polymerase I inhibitor | 0.097 0.09 DBMET00285 | DBMET00285 | |
| 0.03 | 0.244 | 0.075 | Potassium channel (Tandem pore domain) blocker | 0.075 0.047 DBMET02951 | DBMET02951 | |
| 0.008 | 0.229 | 0.06 | Nicotinic acid receptor 2 agonist | 0.06 0.011 DBMET00285 | DBMET00285 | |
| 0.004 | 0.232 | 0.021 | Aminopeptidase P inhibitor | 0.021 0.019 DBMET02951 | DBMET02951 | |
| 0.015 | 0.252 | 0.064 | Protein kinase C theta inhibitor | 0.064 0.031 DBMET02951 | DBMET02951 | |
| 0.005 | 0.244 | 0.016 | Calcitonin gene-related peptide 1 receptor antagonist | 0.016 0.014 DBMET00285 | DBMET00285 | |
| 0.041 | 0.281 | 0.106 | Caspase 3 inhibitor | 0.106 0.082 DBMET02951 | DBMET02951 | |
| 0.025 | 0.269 | 0.056 | Phosphodiesterase 1B inhibitor | 0.056 0.047 DBMET00285 | DBMET00285 | |
| 0.021 | 0.267 | 0.06 | Epithelial sodium channel blocker | 0.06 0.029 DBMET02951 | DBMET02951 | |
| 0.026 | 0.278 | 0.07 | Secretase beta inhibitor | 0.07 0.049 DBMET02951 | DBMET02951 | |
| 0.005 | 0.264 | 0.029 | Bombesin 3 receptor agonist | 0.029 0.006 DBMET02951 | DBMET02951 | |
| 0.03 | 0.29 | 0.071 | Sphingosine 1-phosphate receptor antagonist | 0.071 0.069 DBMET02951 | DBMET02951 | |
| 0.051 | 0.311 | 0.1 | Interleukin 8 antagonist | 0.1 0.097 DBMET00285 | DBMET00285 | |
| 0.025 | 0.288 | 0.087 | Potassium channel (Ca-activated) activator | 0.087 0.068 DBMET02951 | DBMET02951 | |
| 0.015 | 0.288 | 0.118 | HIV-1 reverse transcriptase inhibitor | 0.118 0.023 DBMET00285 | DBMET00285 | |
| 0.005 | 0.285 | 0.036 | Bombesin agonist | 0.036 0.006 DBMET02951 | DBMET02951 | |
| 0.055 | 0.336 | 0.161 | Thiol protease inhibitor | 0.161 0.06 DBMET02951 | DBMET02951 | |
| 0.063 | 0.345 | 0.124 | DNA repair enzyme inhibitor | 0.124 0.064 DBMET00285 | DBMET00285 | |
| 0.074 | 0.357 | 0.135 | ATPase inhibitor | 0.135 0.129 DBMET00285 | DBMET00285 | |
| 0.007 | 0.3 | 0.137 | Cannabinoid CB1 receptor agonist | 0.137 0.012 DBMET02951 | DBMET02951 | |
| 0.031 | 0.326 | 0.081 | Glutathione S-transferase inhibitor | 0.081 0.059 DBMET02951 | DBMET02951 | |
| 0.103 | 0.403 | 0.254 | Peptidyltransferase inhibitor | 0.254 0.048 DBMET00285 0.209 0.088 DBMET02951 | DBMET00285 | |
| 0.014 | 0.318 | 0.039 | Nicotinic acid receptor 1 agonist | 0.039 0.03 DBMET00285 | DBMET00285 | |
| 0.057 | 0.371 | 0.102 | Interleukin 2 antagonist | 0.102 0.084 DBMET02951 | DBMET02951 | |
| 0.033 | 0.349 | 0.125 | Lipid peroxidase inhibitor | 0.125 0.088 DBMET00285 | DBMET00285 | |
| 0.053 | 0.379 | 0.25 | Calpain inhibitor | 0.25 0.065 DBMET02951 | DBMET02951 | |
| 0.004 | 0.336 | 0.047 | Calcitonin gene-related peptide antagonist | 0.047 0.011 DBMET00285 | DBMET00285 | |
| 0.055 | 0.391 | 0.099 | Factor V inhibitor | 0.099 0.072 DBMET02951 | DBMET02951 | |
| 0.072 | 0.431 | 0.227 | Antithrombotic | 0.227 0.147 DBMET02951 | DBMET02951 | |
| 0.121 | 0.486 | 0.189 | MAP kinase kinase 3 inhibitor | 0.189 0.158 DBMET02951 | DBMET02951 | |
| 0.011 | 0.384 | 0.033 | Purinergic P2Y2 antagonist | 0.033 0.024 DBMET00285 | DBMET00285 | |
| 0.021 | 0.4 | 0.074 | Vanilloid 2 antagonist | 0.074 0.012 DBMET02951 | DBMET02951 | |
| 0.025 | 0.412 | 0.055 | Adenine nucleotide translocase inhibitor | 0.055 0.039 DBMET02951 | DBMET02951 | |
| 0.01 | 0.409 | 0.043 | Neuraminidase (Influenza A) inhibitor | 0.043 0.035 DBMET02951 | DBMET02951 | |
| 0.005 | 0.408 | 0.09 | Cannabinoid receptor agonist | 0.09 0.03 DBMET02951 | DBMET02951 | |
| 0.031 | 0.443 | 0.16 | Electron transport complex I inhibitor | 0.16 0.016 DBMET02951 | DBMET02951 | |
| 0.048 | 0.466 | 0.307 | Calpain 2 inhibitor | 0.307 0.11 DBMET02951 | DBMET02951 | |
| 0.041 | 0.459 | 0.284 | Vasodilator | 0.284 0.054 DBMET00285 | DBMET00285 | |
| 0.039 | 0.578 | 0.209 | Transcription factor STAT inhibitor | 0.209 0.125 DBMET02951 | DBMET02951 | |
| 0.011 | 0.572 | 0.063 | Neuropeptide agonist | 0.063 0.037 DBMET02951 | DBMET02951 | |
| 0.029 | 0.6 | 0.205 | Transcription factor STAT3 inhibitor | 0.205 0.127 DBMET02951 | DBMET02951 | |
| 0.022 | 0.6 | 0.132 | Vanilloid agonist | 0.132 0.014 DBMET02951 | DBMET02951 | |
| 0.022 | 0.656 | 0.105 | Interleukin 5 antagonist | 0.105 0.036 DBMET00285 | DBMET00285 | |
| 0.019 | 0.688 | 0.169 | Histone deacetylase SIRT1 inhibitor | 0.169 0.047 DBMET02951 | DBMET02951 | |
| 0.005 | 0.692 | 0.091 | Phosphodiesterase III inhibitor | 0.091 0.027 DBMET00285 | DBMET00285 | |
| 0.004 | 0.764 | 0.072 | Factor VIIa inhibitor | 0.072 0.015 DBMET02951 | DBMET02951 | |
| 0.015 | 0.778 | 0.1 | Nav1.4 sodium channel blocker | 0.1 0.076 DBMET02951 | DBMET02951 | |
| 0.005 | 0.841 | 0.19 | Neurotrophic factor | 0.19 0.033 DBMET02951 | DBMET02951 | |
| 0.005 | 0.854 | 0.105 | Histone deacetylase class III inhibitor | 0.105 0.085 DBMET02951 | DBMET02951 | |
| 0.005 | 0.913 | 0.186 | Interleukin antagonist | 0.186 0.092 DBMET02951 | DBMET02951 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |